Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials

Objectives. Several randomized controlled trials (RCTs) consistently reported better clinical outcomes with radial as compared to femoral access for primary percutaneous coronary intervention (PCI). Nevertheless, heterogeneous use of potent antiplatelet drugs, such as Gp IIb/IIIa inhibitors (GPI), a...

Full description

Bibliographic Details
Main Authors: Stefano Rigattieri, Ernesto Cristiano, Francesca Giovannelli, Antonella Tommasino, Francesco Cava, Barbara Citoni, Domenico Maria Zardi, Andrea Berni, Massimo Volpe
Format: Article
Language:English
Published: Hindawi-Wiley 2021-01-01
Series:Journal of Interventional Cardiology
Online Access:http://dx.doi.org/10.1155/2021/9917407
id doaj-a5fe2e73b26942ce8303cb573888ffab
record_format Article
spelling doaj-a5fe2e73b26942ce8303cb573888ffab2021-06-28T01:50:54ZengHindawi-WileyJournal of Interventional Cardiology1540-81832021-01-01202110.1155/2021/9917407Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized TrialsStefano Rigattieri0Ernesto Cristiano1Francesca Giovannelli2Antonella Tommasino3Francesco Cava4Barbara Citoni5Domenico Maria Zardi6Andrea Berni7Massimo Volpe8Interventional Cardiology UnitInterventional Cardiology UnitInterventional Cardiology UnitInterventional Cardiology UnitInterventional Cardiology UnitInterventional Cardiology UnitInterventional Cardiology UnitInterventional Cardiology UnitDepartment of Clinical and Molecular MedicineObjectives. Several randomized controlled trials (RCTs) consistently reported better clinical outcomes with radial as compared to femoral access for primary percutaneous coronary intervention (PCI). Nevertheless, heterogeneous use of potent antiplatelet drugs, such as Gp IIb/IIIa inhibitors (GPI), across different studies could have biased the results in favor of radial access. We performed an updated meta-analysis and meta-regression of RCTs in order to appraise whether the use of GPI had an impact on pooled estimates of clinical outcomes according to vascular access. Methods. We computed pooled estimates by the random-effects model for the following outcomes: mortality, major adverse cardiovascular events (death, myocardial infarction, stroke, and target vessel revascularization), and major bleedings. Additionally, we performed meta-regression analysis to investigate the impact of GPI use on pooled estimates of clinical outcomes. Results. We analyzed 14 randomized controlled trials and 11090 patients who were treated by radial (5497) and femoral access (5593), respectively. Radial access was associated with better outcomes for mortality (risk difference 0.01 (0.00, 0.01), p=0.03), MACE (risk difference 0.01 (0.00, 0.02), p=0.003), and major bleedings (risk difference 0.01 (0.00, 0.02), p=0.02). At meta-regression, we observed a significant correlation of mortality with both GPI use (p=0.011) and year of publication (p=0.0073), whereas no correlation was observed with major bleedings. Conclusions. In this meta-analysis, the use of radial access for primary PCI was associated with better clinical outcomes as compared to femoral access. However, the effect size on mortality was modulated by GPI rate, with greater benefit of radial access in studies with larger use of these drugs.http://dx.doi.org/10.1155/2021/9917407
collection DOAJ
language English
format Article
sources DOAJ
author Stefano Rigattieri
Ernesto Cristiano
Francesca Giovannelli
Antonella Tommasino
Francesco Cava
Barbara Citoni
Domenico Maria Zardi
Andrea Berni
Massimo Volpe
spellingShingle Stefano Rigattieri
Ernesto Cristiano
Francesca Giovannelli
Antonella Tommasino
Francesco Cava
Barbara Citoni
Domenico Maria Zardi
Andrea Berni
Massimo Volpe
Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
Journal of Interventional Cardiology
author_facet Stefano Rigattieri
Ernesto Cristiano
Francesca Giovannelli
Antonella Tommasino
Francesco Cava
Barbara Citoni
Domenico Maria Zardi
Andrea Berni
Massimo Volpe
author_sort Stefano Rigattieri
title Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
title_short Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
title_full Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
title_fullStr Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
title_full_unstemmed Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
title_sort glycoprotein iib/iiia inhibitors may modulate the clinical benefit of radial access as compared to femoral access in primary percutaneous coronary intervention: a meta-regression and meta-analysis of randomized trials
publisher Hindawi-Wiley
series Journal of Interventional Cardiology
issn 1540-8183
publishDate 2021-01-01
description Objectives. Several randomized controlled trials (RCTs) consistently reported better clinical outcomes with radial as compared to femoral access for primary percutaneous coronary intervention (PCI). Nevertheless, heterogeneous use of potent antiplatelet drugs, such as Gp IIb/IIIa inhibitors (GPI), across different studies could have biased the results in favor of radial access. We performed an updated meta-analysis and meta-regression of RCTs in order to appraise whether the use of GPI had an impact on pooled estimates of clinical outcomes according to vascular access. Methods. We computed pooled estimates by the random-effects model for the following outcomes: mortality, major adverse cardiovascular events (death, myocardial infarction, stroke, and target vessel revascularization), and major bleedings. Additionally, we performed meta-regression analysis to investigate the impact of GPI use on pooled estimates of clinical outcomes. Results. We analyzed 14 randomized controlled trials and 11090 patients who were treated by radial (5497) and femoral access (5593), respectively. Radial access was associated with better outcomes for mortality (risk difference 0.01 (0.00, 0.01), p=0.03), MACE (risk difference 0.01 (0.00, 0.02), p=0.003), and major bleedings (risk difference 0.01 (0.00, 0.02), p=0.02). At meta-regression, we observed a significant correlation of mortality with both GPI use (p=0.011) and year of publication (p=0.0073), whereas no correlation was observed with major bleedings. Conclusions. In this meta-analysis, the use of radial access for primary PCI was associated with better clinical outcomes as compared to femoral access. However, the effect size on mortality was modulated by GPI rate, with greater benefit of radial access in studies with larger use of these drugs.
url http://dx.doi.org/10.1155/2021/9917407
work_keys_str_mv AT stefanorigattieri glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT ernestocristiano glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT francescagiovannelli glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT antonellatommasino glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT francescocava glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT barbaracitoni glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT domenicomariazardi glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT andreaberni glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
AT massimovolpe glycoproteiniibiiiainhibitorsmaymodulatetheclinicalbenefitofradialaccessascomparedtofemoralaccessinprimarypercutaneouscoronaryinterventionametaregressionandmetaanalysisofrandomizedtrials
_version_ 1721357214320427008